NCT00856492
Clinical Trial Information
Trial Number: NCT00856492 (ClinicalTrials.gov)
Disease Type:
- Breast Neoplasm - Breast Cancer (Invasive)
Trial Title:
"A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer"
Study ID:
S0800
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00856492-D2 | These datasets contain the results reported in NPJ Breast Cancer (Fanucci et al., NPJ Breast Cancer, 2023). This clinical dataset contains participant-level data (one row per participant), including evaluability, treatment, demographic, and pathologic data. NCT00856492-D1 contains a list of specimens (one specimen per row). |
| NCT00856492-D1 | These datasets contain the results reported in NPJ Breast Cancer (Fanucci et al., NPJ Breast Cancer, 2023). The NCT00856492-D2 clinical dataset contains participant-level data (one row per participant), including evaluability, treatment, demographic, and pathologic data. This dataset contains a list of specimens (one specimen per row). |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®